What Phase 3 Results Mean for Acne Patients
Phase 3 clinical trials are the final big test before a new acne treatment can hit the market. They involve hundreds or thousands of real patients with acne to check if the drug works well and is safe over several months. Good results here mean patients could soon have better options to clear their skin without as many side effects.
Take denifanstat, also called ASC40, a new pill from Ascletis for moderate to severe acne. In its Phase 3 trial, it beat placebo on every main goal, cutting down acne lesions a lot more. Patients saw big improvements, and side effects were only mild or moderate, with nothing serious linked to the drug. This could give people a fresh way to fight tough acne, especially since the trial wrapped up strong and got presented at a major dermatology meeting in 2025.[2]
Clascoterone cream has shown promise too. In earlier studies leading to Phase 3 success, about 20 percent of patients got nearly clear skin, compared to just 8 percent on fake treatment. It cut both red, bumpy lesions and blackheads or whiteheads fast, starting as early as two weeks. Long-term use up to nine months kept working for half the patients, with mostly just mild skin irritation.[1]
Topical combos are winning big in Phase 3. One gel with clindamycin, adapalene, and benzoyl peroxide cleared or almost cleared skin for half the users. It slashed lesion counts by over 70 percent in both men and women. Another lotion with tazarotene worked well for moderate to severe cases in two big trials.[3][7]
Hormone treatments shone in Phase 3 for women. Pills like ethinylestradiol with drospirenone or dienogest dropped total lesions by 55 to 67 percent, way better than placebo. Real-world use showed up to 94 percent reduction over a year, with many getting fully clear skin and low risks.[1]
Spironolactone, often paired with benzoyl peroxide, beat out doxycycline in a trial with women who had moderate acne. It reduced spots more and boosted quality of life, with good safety.[1]
These Phase 3 wins mean acne patients might get stronger, safer treatments soon. Drugs that hit all goals with few issues could mean faster clearing, less scarring, and happier daily life. Experts are building consensus on staples like isotretinoin too, to make sure doctors use them right for severe cases.[4]
Patients should talk to dermatologists about these updates, as approvals follow soon after solid Phase 3 data.
Sources
https://pmc.ncbi.nlm.nih.gov/articles/PMC12691598/
https://www.prnewswire.com/news-releases/ascletis-announces-china-national-medical-products-administration-acceptance-of-new-drug-application-for-denifanstat-asc40-a-first-in-class-fasn-inhibitor-for-acne-treatment-302637708.html
https://jddonline.com/acne-resource-center-articles/
https://clinicaltrials.gov/study/NCT07296523
https://pubmed.ncbi.nlm.nih.gov/41329145/?fc=None&ff=20251211211428&v=2.18.0.post22+67771e2
